What is Inflection Biosciences?
Inflection Biosciences Ltd operates as a specialized drug development entity dedicated to the discovery and advancement of innovative small molecule therapeutics. The company's core competency lies in addressing critical unmet medical needs, particularly within the domains of cancer, autoimmune disorders, and inflammatory diseases. Their current pipeline is anchored by sophisticated assets such as IBL-202, a dual mechanism kinase inhibitor, and AUM302, which is being developed in collaboration with AUM Biosciences. By leveraging rigorous research and development protocols, Inflection Biosciences aims to bridge the gap between laboratory discovery and clinical application, positioning itself as a vital player in the pharmaceutical innovation ecosystem.
How much funding has Inflection Biosciences raised?
Inflection Biosciences has raised a total of $785K across 1 funding round:
Private Equity
$785K
Private Equity (2015): $785K, investors not publicly disclosed
Key Investors in Inflection Biosciences
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Inflection Biosciences?
With the recent influx of capital, Inflection Biosciences is well-positioned to accelerate its clinical development milestones and expand its research capabilities. The strategic focus will likely remain on the advancement of its lead kinase inhibitors, ensuring that these therapeutic candidates move efficiently through the regulatory pipeline. As the company scales its operations, the emphasis will shift toward strengthening existing partnerships and potentially exploring new collaborative frameworks to maximize the commercial viability of its drug portfolio. Investors will be closely monitoring the progression of IBL-202 and AUM302 as key indicators of the company's long-term growth trajectory and its ability to deliver transformative outcomes in the oncology and immunology sectors.
See full Inflection Biosciences company page
